Clinical Trial Update: Adjuvant Trastuzumab, Pertuzumab Plus Docetaxel in the Treatment of Early HER2-positive Breast Cancer [Phase 3]

View source ↗

Summary

This update reports on a Phase 3 adjuvant trial evaluating trastuzumab and pertuzumab in combination with docetaxel for early HER2-positive breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• Pertuzumab (pertuzumab)
• Trastuzumab (trastuzumab)

Snippet

Sponsor: Helsinki University Central Hospital | Conditions: Breast Cancer | Phase 3 | Status: ACTIVE_NOT_RECRUITING